HBM Partners

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

1000Farmacie is the leading pharmacy marketplace in Italy, operating an online shopping platform that connects consumers with a network of independent pharmacies. The company provides a wide range of pharmaceutical products, allowing users to purchase healthcare items at competitive prices. With a focus on convenience, 1000Farmacie ensures same-day delivery of products to specified locations, helping customers save time and money while accessing essential healthcare products from authorized pharmacies.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Antiva Biosciences, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral therapies for human papillomavirus (HPV) infections. Established in 2012, the company aims to prevent cancer by treating precancerous lesions associated with HPV. Antiva's innovative approach includes localized therapeutics and small molecule antivirals that target HPV and other viral infections. The company is currently conducting clinical trials for high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias. Through its medicinal chemistry platform, Antiva strives to enhance health outcomes for patients affected by HPV-related diseases and other viral infections.

Shape Memory Medical Inc is a medical device company located in Santa Clara, California, focused on creating innovative therapeutic solutions for the peripheral vascular, cardiovascular, and neurovascular markets. The company specializes in utilizing Shape Memory Polymer (SMP) technology, which was originally developed at Texas A&M University and Lawrence Livermore National Laboratory. Shape Memory Medical is notable for being the first to introduce an FDA-cleared medical device incorporating SMP technology specifically for the vascular market, thereby enhancing the capabilities of physicians in patient care. The team at Shape Memory Medical possesses significant expertise in SMP foam technology and the commercialization of medical devices, positioning the company as a leader in its field.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

Upstream Bio Inc is a clinical-stage biotechnology company dedicated to developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary focus is on verekitug, an antibody therapy designed to inhibit the Thymic Stromal Lymphopoietin receptor. This receptor is a key target in the inflammatory response, influencing various immune cells and signaling pathways involved in both common and rare illnesses. By targeting TSLP, Upstream Bio aims to address the underlying mechanisms of severe asthma and related conditions, positioning itself as a significant player in the field of immunotherapy.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Dren Bio is a biotechnology company that specializes in protein engineering technologies aimed at depleting pathogenic cells, protein aggregates, and other disease-causing agents. The company operates under a holding business model, developing a diverse portfolio of projects that function as stand-alone assets. Dren Bio's platform is designed to address a range of health conditions, including hematologic neoplasms, solid tumors, autoimmune disorders, and diseases associated with protein aggregation. By focusing on innovative protein-based technologies, Dren Bio enables healthcare professionals to manage and treat various serious diseases more effectively.

Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Vascular Dynamics, Inc., established in 2008, is a medical device company based in Irvine, California. It specializes in developing and commercializing minimally invasive treatments for drug-resistant hypertension. The company's flagship product, MobiusHD, is a catheter-delivered implant designed to stimulate vasodilation, reduce heart rate, and modulate kidney response by amplifying the natural baroreceptor response in the carotid sinus. Vascular Dynamics' team comprises over 75 years of collective experience in developing and commercializing medical devices.

Farmalisto is an online pharmacy that serves as a bridge between healthcare providers and patients in Colombia and Mexico. Founded in 2013 and based in Bogotá and Mexico City, the company specializes in offering a wide array of products, including pharmaceuticals and health-related items such as haircare, dental products, and baby hygiene necessities. In addition to product sales, Farmalisto enhances the pharmaceutical landscape by providing logistics, marketing, and disease management services tailored for pharmaceutical companies. Its platform not only facilitates easy access to medicines, particularly for chronic and complex conditions, but also includes home assistance and patient support programs, ensuring that patients can receive necessary care from the comfort of their homes or offices.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for hypertension. The company is advancing its lead product candidate, MLS-101, a highly selective and potent aldosterone synthase inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. Mineralys aims to provide a targeted treatment for patients with uncontrolled hypertension, particularly those who do not achieve adequate blood pressure control despite using multiple antihypertensive medications. By addressing the underlying factors associated with elevated aldosterone levels, Mineralys seeks to improve treatment outcomes for individuals suffering from this condition.

Adrenomed AG is a biopharmaceutical company based in Hennigsdorf, Germany, focused on developing monoclonal antibody therapies for critical conditions such as sepsis and acute heart failure. Founded in 2009, the company’s lead product candidate, Adrecizumab, is a novel humanized monoclonal antibody designed to target Adrenomedullin, a peptide hormone crucial for maintaining vascular integrity. This first-in-class treatment aims to address life-threatening situations characterized by vascular leakage and shock, offering a potential solution for patients with limited treatment options. Adrenomed employs a unique approach by combining its therapeutic antibody with a specific diagnostic tool that uses Adrenomedullin as a biomarker to identify suitable patients for treatment. The company holds a strong intellectual property position, with patents granted in major markets, ensuring its innovative therapies are well protected as they progress through clinical development.

Aculys Pharma is a pharmaceutical company that develops drugs and innovative medical treatments for neurological and psychiatric disorders.

Fore Biotherapeutics is a clinical-stage biotechnology company focused on developing precision oncology treatments for cancer patients with specific genetic mutations. By utilizing functional genomics, the company aims to create a pipeline of targeted therapies that address unmet medical needs in oncology. Their drug development process involves replicating naturally occurring mutations in laboratory settings, allowing for the testing of these mutations' effects on signaling pathways and their responsiveness to various compounds. This approach not only facilitates the identification of novel target mutations but also helps biopharmaceutical companies expand the subgroups of cancer patients who may benefit from existing therapies.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Neuron23, Inc. is a biotechnology company focused on developing and manufacturing innovative medicines for genetic disorders, particularly targeting neurological and immunological diseases. Founded in 2018 and headquartered in South San Francisco, California, with an additional office in Munich, Germany, the company utilizes advanced artificial intelligence technology and cutting-edge genetic research to enhance drug discovery. Neuron23 aims to create effective treatments for conditions such as Parkinson's disease and Alzheimer's disease, leveraging its AI-enabled platforms to identify and develop therapeutics that address the needs of patients suffering from these debilitating disorders.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

Karius, Inc. is a life sciences company based in Redwood City, California, with an additional office in Menlo Park. Founded in 2014, Karius specializes in generating genomic insights for infectious diseases through its innovative Karius Test. This non-invasive blood test utilizes sequencing of microbial cell-free DNA to identify and quantify a wide range of pathogens, including bacteria, DNA viruses, fungi, and parasites. The Karius Test is particularly useful in the diagnosis of complicated pneumonia, infections in immunocompromised patients, and endocarditis, enabling clinicians to make rapid and informed treatment decisions. Karius operates a CLIA-certified and CAP-accredited laboratory, providing high-complexity clinical laboratory testing and offering services for pathogen biomarker detection aimed at biopharmaceutical companies. The company is dedicated to advancing the understanding and management of infectious diseases, striving for a future where these conditions pose less of a threat to human health.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Sphingotec GmbH, established in 2002 and based in Brandenburg, Germany, specializes in developing blood-based protein biomarkers for the diagnosis, prediction, and monitoring of acute medical conditions. These conditions include acute heart failure, acute kidney injury, and circulatory shock. The company's portfolio also extends to developing monoclonal antibody therapies in combination with targeted diagnostic tests, aiming to improve the management and recovery of critically ill patients.

iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics aimed at improving outcomes for cancer patients. Founded in 2011 and headquartered in Gosselies, Belgium, with additional operations in Cambridge, Massachusetts, the company is advancing a pipeline of innovative drug candidates. Notable among these is EOS-850, a small molecule antagonist targeting the adenosine A2a receptor, currently undergoing an open-label Phase 1/2a clinical trial in adult patients. Another key candidate is EOS-448, an antagonist of TIGIT, which is also in Phase 1/2a trials. iTeos leverages expertise in tumor immunology to create small molecule immunomodulators designed to counteract cancer-induced immune suppression, thereby enhancing the effectiveness of existing treatments and emerging immunotherapies.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Hookipa Pharma Inc. is a clinical stage biopharmaceutical company focused on developing innovative immunotherapeutics for infectious diseases and cancers through its proprietary arenavirus platform. The company employs its advanced Vaxwave and TheraT technologies to stimulate robust immune responses, generating antigen-specific killer T cells and antibodies. Hookipa's lead candidate for infectious diseases, HB-101, is currently undergoing a Phase II clinical trial targeting patients awaiting kidney transplants from cytomegalovirus-positive donors. In oncology, its product candidates HB-201 and HB-202 are in preclinical studies aimed at treating human papillomavirus-positive cancers. Additionally, Hookipa collaborates with Gilead Sciences to create therapies for chronic Hepatitis B and HIV infections. Founded in 2011, the company is headquartered in New York, New York.

ConnectRN, Inc. is a technology-driven company that operates an online platform designed to connect healthcare institutions with qualified nursing staff. Incorporated in 2014 and based in Newton, Massachusetts, the platform enables hospitals and healthcare providers to communicate effectively with available nurses through an alert system that notifies them of open shifts via mobile devices. In addition to facilitating job placements, ConnectRN provides tools that streamline communication between nurses and nurse managers, ensuring that staffing needs are met efficiently. The company aims to enhance the nursing community by offering access to opportunities, support, and a network that fosters collaboration among clinicians.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

i-Optics, established in 2006, is a Dutch medical device company specializing in corneal diagnostic solutions. It offers the Cassini Corneal Shape Analyzer, a pioneering tool using color LED technology to precisely measure corneal astigmatism, enhancing premium IOL planning. Additionally, i-Optics provides the EasyScan, a zero-dilation retinal imaging system for diagnosing various eye diseases. Their suite of examinations, including corneal topography, pupillometry, and full-color photography, empowers cataract surgeons to better understand corneal properties, improving surgical outcomes and increasing patient satisfaction.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for serious women's health infections, particularly those that have been historically overlooked. Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in antibiotics for gynecologic infections. Its lead product, Solosec (secnidazole), is a next-generation 5-nitroimidazole antibiotic designed for the one-time oral treatment of bacterial vaginosis. This drug is characterized by its enhanced pharmacokinetic properties, allowing for effective and well-tolerated delivery in a single dose. Symbiomix Therapeutics operates as a subsidiary of Lupin Inc.

APR Applied Pharma Research s.a. is a pharmaceutical company based in Balerna, Switzerland, established in 1990. It specializes in the identification, development, manufacturing, and licensing of healthcare products across various therapeutic areas, including cancer supportive care, CNS disorders, dermatology, gynecology, and pain management. The company focuses on creating oral and topical formulations, offering a range of prescription and consumer healthcare products such as treatments for acute pain, cough, cold, and more. APR's innovative drug delivery systems and science-driven formulation technology enable it to address unmet medical needs, particularly in specialized therapeutic areas and rare diseases. With a strategic focus on markets in Europe and the United States, as well as rapidly growing regions like China, Russia, and Latin America, APR aims to improve the lives of patients and empower families through novel approaches to disease management.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Gynesonics, Inc. is a medical device company focused on developing innovative solutions for women's health, specifically addressing symptomatic uterine fibroids. Founded in 2005 and headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands, Gynesonics offers the Sonata System, a minimally invasive treatment that utilizes sonography guidance for the transcervical ablation of fibroids. This incision-free approach provides a safe and effective alternative to traditional surgical methods such as hysterectomy or myomectomy, aiming to alleviate severe menstrual symptoms associated with fibroids. Gynesonics is dedicated to improving the quality of care for women by offering advanced technologies that enhance treatment options in gynecology.

Odyssey Thera, Inc. is a biopharmaceutical company based in San Ramon, California, dedicated to identifying and developing innovative therapies for cancer treatment. The company employs a cellular pharmacology strategy to decipher biologically-relevant pathways in living human cells, enhancing the processes of target and drug discovery. Odyssey Thera's product pipeline features small molecule inhibitors that target crucial signaling nodes in human cancer cells. Originally incorporated as Odyssey Pharmaceuticals in 2002, the company has evolved to focus on advancing methods for environmental chemical toxicity assessment alongside its therapeutic development efforts.

Reha Technology AG is a Swiss company specializing in the design, manufacture, and global distribution of advanced robotic-assisted systems for neurorehabilitation. Founded in 2012 and headquartered in Olten, Switzerland, the company focuses on developing devices that enhance the quality of life for individuals affected by neurological movement disorders, injuries, or disabilities. Its flagship product, the G-EO System, is designed for gait rehabilitation and features capabilities that realistically simulate stair climbing. Reha Technology aims to empower patients by improving their functional abilities and skills necessary for personal self-care and independence in daily life. With a worldwide distributor network, the company has established direct operations in the United States and India, and it plans to expand further into Latin America.

Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents to address serious infections. The company's lead product candidate, XENLETA, is the first systemic pleuromutilin antibiotic approved by the U.S. Food and Drug Administration for the treatment of community-acquired bacterial pneumonia. In addition to XENLETA, Nabriva is developing CONTEPO, a potential first-in-class epoxide antibiotic aimed at treating complicated urinary tract infections, including acute pyelonephritis. The company is also involved in clinical trials for other indications, including pediatric infections and sexually transmitted infections. Founded in 2005 and headquartered in Dublin, Ireland, Nabriva was previously known as Nabriva Therapeutics Forschungs GmbH before rebranding in 2007.

Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.

Gemin X Pharmaceuticals is focused on the discovery, development, and commercialization of innovative cancer therapeutics aimed at improving patient outcomes. The company’s research centers on the Bcl-2 cell death regulation pathway, leading to the development of GX15-070, also known as obatoclax. This small molecule is designed to selectively trigger programmed cell death, or apoptosis, and may also promote autophagy in cancer cells. Obatoclax has demonstrated encouraging results in preclinical and early clinical studies and is currently undergoing Phase 2 clinical trials, both as a standalone treatment and in combination therapies. In addition to obatoclax, Gemin X is developing GMX1777, an inhibitor of NAD+ synthesis, among other oncology products, providing patients with potential relief from various cancer conditions. The company holds patent protection for obatoclax until 2025.

Asthmatx is a medical device company based in Mountain View, California, founded in 2003 and now operating as a subsidiary of Boston Scientific. The company specializes in developing and commercializing therapeutic treatments for asthma. Asthmatx has created a technology that delivers controlled thermal energy to the airways of adult patients to reduce airway smooth muscle mass through a procedure known as Bronchial Thermoplasty. Their flagship product is the Alair System, an interventional medical device designed for bronchoscopic treatment of moderate to severe asthma.

Newron Pharmaceuticals S.p.A. is a clinical-stage biopharmaceutical company dedicated to the research and development of therapies for central and peripheral nervous system disorders, as well as pain management. Founded in 1999 and headquartered in Bresso, Italy, the company has a diverse pipeline of treatments, including Xadago (safinamide) for Parkinson's disease, which is commercially available in several regions. Newron is advancing several promising candidates in clinical development, such as Sarizotan for Rett syndrome, Ralfinamide for specific rare pain indications, and Evenamide, envisioned as the first add-on therapy for positive symptoms of schizophrenia. The company conducts its research and development activities primarily in Italy and the United States.

Anadys Pharmaceuticals is a biopharmaceutical company based in San Diego, California, focused on developing treatments for chronic hepatitis C viral infections. The company is primarily working on ANA598, a direct-acting antiviral agent designed to inhibit the hepatitis C virus. Additionally, Anadys is investigating ANA773, an oral small-molecule inducer of endogenous interferons that activates the Toll-like receptor 7 pathway. Founded in 1992, Anadys Pharmaceuticals operates as a subsidiary of Hoffmann-La Roche Inc.

AGY Therapeutics is a biopharmaceutical company based in South San Francisco, California, founded in 1998. The company specializes in discovering, developing, and commercializing treatments for diseases of the central nervous system (CNS). Its focus areas include neurodegenerative diseases, CNS injuries, stroke, cognitive diseases, and schizophrenia. AGY Therapeutics has a pipeline of novel therapeutic programs, both in clinical and preclinical development, aimed at addressing significant unmet medical needs. The company uses its proprietary platform for functional gene discovery and mapping specific pathways underlying CNS diseases to identify potential target proteins that can modulate disease progression. This approach is designed to pave the way for innovative CNS therapeutics.

Aspreva Pharmaceuticals Corp is a pharmaceutical company based in Victoria, British Columbia, dedicated to developing and commercializing new indications for existing drugs aimed at underserved patient populations. The company specializes in identifying late-stage and approved medications that have the potential for significant therapeutic benefits in less common diseases. Through a strategy known as "indication partnering," Aspreva collaborates with other pharmaceutical and biopharmaceutical companies to gain rights for the development of these drugs in new therapeutic areas. This approach encompasses clinical research, regulatory approvals, and the commercialization of products tailored for complex diseases and specialized patient groups. By focusing on innovative therapeutic solutions, Aspreva aims to address unmet medical needs and improve patient outcomes.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other proliferative diseases. Established in 1992 and headquartered in Berkeley Heights, New Jersey, the company specializes in oral treatments that influence various phases of cell cycle control. Its oncology pipeline features several promising candidates, including CYC065, a cyclin-dependent kinase (CDK) inhibitor currently undergoing Phase I trials for solid tumors and chronic lymphocytic leukemia, and CYC140, a polo-like kinase (PLK) inhibitor in Phase I trials for advanced leukemias. Additionally, Cyclacel is advancing sapacitabine, an oral nucleoside analogue, in combination studies for patients with BRCA mutations, along with ongoing Phase III trials for acute myeloid leukemia. The company collaborates with the University of Texas MD Anderson Cancer Center to assess the safety and efficacy of its treatments in hematological malignancies and has partnered with ManRos Therapeutics for the development of oral seliciclib capsules aimed at treating cystic fibrosis.

Sloning BioTechnology specializes in the production of high-quality, customized DNA molecules at an industrial scale. Its proprietary Slonomics technology platform enables reliable and cost-effective synthesis, overcoming traditional sequence limitations through a fully-automated robotic system. Additionally, the company offers synthetic biology tools to support its clients' research and development efforts.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically aimed at treating various types of cancer. Founded in 1997 and based in Santa Monica, California, Agensys develops innovative products targeting tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. The company is dedicated to providing effective treatment options for patients battling these cancers. In 2007, Agensys became a subsidiary of Astellas Pharma US, Inc., further enhancing its capabilities in the oncology therapeutic space.

Syrrx Inc is a biotechnology company that specializes in the development of novel small molecule drugs aimed at treating cancer, metabolic diseases, and inflammation. By leveraging its expertise in high-throughput structural biology, Syrrx is able to determine the three-dimensional structures of drug targets that have been validated in human clinical trials. This foundational work supports their iterative, structure-based drug design programs, which efficiently generate potential drug candidates. The company has established partnerships for the development and commercialization of its designed human dipeptidyl peptidase IV (DPP IV) inhibitors for the treatment of type 2 diabetes and other significant diseases. Additionally, Syrrx has a strategic alliance focused on discovering and early developing inhibitors that target human histone deacetylases (HDACs) and 11β-hydroxysteroid dehydrogenase type 1 (HSD1), further expanding its therapeutic portfolio.